|
|
|
| Effect of Sequential Therapy with Azithromycin Combined Shuanghuanglian Oral Liquid on the T Lymphocyte Subsets, Serum Inflammatory Cytokines Levels of Children with Mycoplasma Pneumonia |
| WANG Meng, ZHANG Xiuqin, YANG Jing, et al |
| Shaanxi Second People's Hospital, Shaanxi Xi'an 710005, China |
|
|
|
|
Abstract Objective: To explore the effect of sequential therapy with azithromycin combined with shuanghuanglian oral liquid on the T lymphocyte subsets, serum interleukin-6 (IL-6), tumor necrosis factor (TNF)-α and high sensitivity C-reactive protein (hs-CRP) levels of children with mycoplasma pneumonia. Methods: 172 cases of children with mycoplasma pneumonia in our hospital from March 2015 to December 2016 were selected. According to simple random method, all the patients were divided into two groups with 86 cases in each group. Sequential therapy with azithromycin were given to both groups and shuanghuanglian oral liquid was given to the observation group additionally. The clinical effect, T lymphocyte subsets, serum IL-6, TNF-α and hs-CRP levels before and after treatment were compared between two groups. Results: The total effective rate of observation group was 96.51%, which was significantly higher than that of the control group (88.37%) (P<0.05). The T lymphocyte subsets CD3+, CD4+ ratio, CD4+/CD8+ of both groups of children after treatment were significantly higher than those before treatment(P<0.01), the CD8+, serum IL-6, TNF-α and hs-CRP levels were significantly lower than those before treatment, and the improvement of the indicators mentioned above in the observation group were more obvious than those of the control group. Between groups, statistically significant at different times within the group (P<0.01). No significant difference was found in the incidence of adverse reactions between two groupsP>0.05). Conclusion: Azithromycin sequential therapy combined with Shuanghuanglian oral liquid could effectively improve the immune function, reduce inflammatory response with high safety for the children with mycoplasma pneumonia.
|
|
|
|
|
|
[1] 任明星,薛国昌,沈琳娜,等.甲泼尼龙联合阿奇霉素治疗小儿难治性支原体肺炎的疗效与安全性分析[J].中国全科医学,2015,18(5):588~591.
[2] 贾静.双黄连口服液的临床应用评价[J].中国医院用药评价与分析,2013,13(2):110~112.
[3] 陆权.童社区获得性肺炎管理指南(试行)(上)[J].中华儿科杂志,2007,45(2):83~90.
[4] 罗钦宏,梁锦枝,黄艳琼,等.痰热清联合阿奇霉素治疗小儿支原体肺炎的疗效及安全性的Meta分析[J].中成药,2014,36(4):702~709.
[5] 何谭娴,黄建萍.小儿支原体肺炎治疗的研究进展[J].医学综述,2014,20(8):1432~1434.
[6] 樊树华,贺一新.双黄连口服液(儿童型)联合阿奇霉素治疗小儿支原体肺炎的临床研究[J].中国实用医药,2017,12(15):114~115.
[7] 郭聪,贺一新.双黄连口服液(儿童型)联合阿奇霉素治疗小儿支原体肺炎效果观察[J].实用中医药杂志,2017,33(7):818~819.
[8] 赵胃胃,赵华,王鑫.儿童肺炎支原体肺炎发病机制的研究进展[J].中华临床医师杂志(电子版),2015,9(20):3759~3763.
[9] 王臻,李雅春,陈璐.儿童难治性肺炎支原体肺炎的早期识别[J].中国当代儿科杂志,2015,17(11):1189~1192. |
|
|
|
2018, Vol. 24 
